Three factors that may influence the success of clozapine rechallenge after myocarditis are severity of the original acute myocarditis, time between the myocarditis event and rechallenge, and rate of clozapine dose titration during rechallenge.
There is no established measure for assessing the severity of nonfatal myocarditis. The 2 cases with the very high C-reactive protein and eosinophil counts (cases 6 and 8) may have been severe, as may those with measured left ventricular impairment (cases 4-8) . The 1 patient with severe myocarditis by these measures who was successfully rechallenged (case 4) had exceptionally slow dose titration at reinitiation, and subsequent echocardiography showed normal left ventricular function.
With regard to the possible benefit of a delay after the development of the initial episode of myocarditis, cases 7 and 8 indicate no such benefit, and a successful rechallenge commenced 9 days after the onset of myocarditis and involved more rapid introduction of clozapine than in the first instance (case 1).
In only 1 case of successful rechallenge was the rate of dose titration exceptionally slow (case 4). None of the unsuccessful instances of rechallenge involved slow dose titration.
Of 5 published reports of rechallenge after clozapine-induced myocarditis, 3, 4, [6] [7] [8] rechallenge was successful in 4 instances. 3, 4, 6, 8 In the unsuccessful case, 7 clozapine treatment was initiated about 6 weeks after the first episode, and the dose was increased by 12.5 mg every third day. Clozapine treatment was ceased after mild illness and electrocardiographic changes, though without an elevation in troponin. Details of the dose titration regimen for the successful cases are sketchy or nonexistent.
Across the total of 13 cases now described, there are not sufficient instances of rechallenge, successful and unsuccessful, to identify factors that may improve the outcome. Some authors have recommended slow initiation of clozapine during rechallenge. 6, 8 There is no added harm in introducing clozapine very slowly. If a repeat of myocarditis can be avoided by this strategy, clozapine may yield a long-term benefit for the patient. 5, 12.5, 12.5, 18.75, 18.75, 18.75, 25 No rise in troponin in first 6 wk 
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In conclusion, the previous occurrence of clozapine-related myocarditis is apparently not always a contraindication to the reintroduction of clozapine treatment. Any decision to rechallenge with clozapine should be made with the consent of the patient and the patient's family after communication of the potential benefits and risks. Rechallenge then is best conducted with considerable caution (very slow dose titration) and an elevated degree of monitoring. 2 
